Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLLEmily C. Liang, Jordan Gauthier, Aya Albittar et al.|Blood Advances|2023Cited by 34
Development and validation of predictive models of early immune effector cell–associated hematotoxicityEmily C. Liang, Jordan Gauthier, Jennifer J. Huang et al.|Blood Advances|2024Cited by 11
Real-World Comparison of Lisocabtagene Maraleucel (Liso-Cel) and Axicabtagene Ciloleucel (Axi-Cel): Efficacy & ToxicityAndrew J. Portuguese, Jordan Gauthier, Natalie Wuliji et al.|Transplantation and Cellular Therapy|2024Cited by 9
T-Cell Large Granular Lymphocyte Population Involving Chimeric Antigen Receptor-Modified T (CAR T) Cells in Patients with Cytopenia after CD19-Targeted CAR T-Cell Therapy: Case SeriesAya Albittar, Alexandre V. Hirayama, Alireza Torabi et al.|Transplantation and Cellular Therapy|2024Cited by 6
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow upAndrew J. Portuguese, Jordan Gauthier, Jennifer J. Huang et al.|Haematologica|2025Cited by 4